¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"cell factor"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
  • cell body
    ¼¼Æ÷ü
  • cell color ratio
    ÀûÇ÷±¸»ö¼Òºñ
  • cell culture
    ¼¼Æ÷¹è¾ç
  • cell cycle
    ¼¼Æ÷ÁÖ±â
  • cell death
    ¼¼Æ÷»ç
  • cell dedifferentiation
    ¼¼Æ÷Å»ºÐÈ­
  • cell division
    ¼¼Æ÷ºÐ¿­
  • cell envelope
    ¼¼Æ÷²®Áú, ¼¼Æ÷ÇǸ·
  • cell fusion
    ¼¼Æ÷À¶ÇÕ
  • cell inclusion
    ¼¼Æ÷Æ÷ÇÔ¹°, ¼¼Æ÷ºÀÀÔü
  • cell interaction
    ¼¼Æ÷»óÈ£ÀÛ¿ë
  • cell labeling technique
    ¼¼Æ÷Ç¥Áö±â¹ý
  • cell lethality
    ¼¼Æ÷Ä¡»çÀ²
  • cell line
    ¼¼Æ÷ÁÖ, ¼¼Æ÷°è
  • cell loss
    ¼¼Æ÷¼Ò½Ç
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
  • cell membrane permeability
    ¼¼Æ÷¸·Åõ°ú¼º
  • cell surface receptor
    ¼¼Æ÷Ç¥¸é¼ö¿ëü
  • cell-associated virus
    ¼¼Æ÷ºÎÂø¹ÙÀÌ·¯½º
  • cell-mediated cytolysis
    ¼¼Æ÷¸Å°³¼¼Æ÷¿ëÇØ
  • cell-mediated cytotoxicity
    ¼¼Æ÷¸Å°³¼¼Æ÷µ¶¼º
  • cell-mediated hypersensitivity
    ¼¼Æ÷¸Å°³°ú¹Î
  • cell-mediated immunity
    ¼¼Æ÷¸Å°³¸é¿ª
  • cell-mediated reaction
    ¼¼Æ÷¸Å°³¹ÝÀÀ
  • cell-mediated response
    ¼¼Æ÷¸Å°³¹ÝÀÀ
  • cell-mediated immunodeficiency syndrome
    ¼¼Æ÷¸Å°³¸é¿ª°áÇÌÁõÈıº
  • cell-mediated lympholysis test
    ¼¼Æ÷¸Å°³¸²ÇÁ±¸¿ëÇØ½ÃÇè
  • centroacinar cell
    »ù²Ê¸®Á߽ɼ¼Æ÷
  • chief cell
    À¸¶ä¼¼Æ÷
  • Chinese hamster ovary cell
    Áß±¹ºñ´ÜÅÐÁã³­¼Ò¼¼Æ÷
  • chromaffin cell
    ģũ·Ò¼¼Æ÷, Å©·Òģȭ¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
  • Tzanck cell
    Á¤Å© ¼¼Æ÷
  • abnormality of cell interaction
    ¼¼Æ÷»óÈ£ÀÛ¿ëÀÌ»ó
  • accessory cell
    º¸Á¶¼¼Æ÷, ºÎ¼ö¼¼Æ÷
  • acidophilic cell
    È£»ê¼º¼¼Æ÷
  • acinar cell
    ¼±Æ÷ ¼¼Æ÷(àÍøàá¬øà)
  • acinar cell
    ¼±¹æ¼¼Æ÷(¡­á¬øà)
  • acinic cell carcinoma
    ¼±¹æ¼¼Æ÷¾ÏÁ¾(¡­á¬øàäßðþ)
  • acinic cell tumor
    ¼±¹æ¼¼Æ÷Á¾(¡­á¬øàðþ)
  • activation, polyclonal B cell
    ´Ù¼¼Æ÷±º B¼¼Æ÷Ȱ¼º, ¿©·¯¹«¸® B¼¼Æ÷Ȱ¼º
  • adamantinoid basal cell carcinoma
    ¹ý¶û Á¾¾ç(ÛöÕË ðþåÆ) ±âÀú¼¼Æ÷¾Ï(Ðñî¼á¬øàäß)
  • adcc(antibody dependent cell mediated cytotoxicity)
    Ç×üÀÇÁ¸¼¼Æ÷¸Å°³¼¼Æ÷µ¶¼º(ù÷ô÷ëîðíá¬øàØÚË¿á¬øàÔ¸àõ)
  • adenoid basal cell carcinoma
    ¼±»ó(àÍßÒ) ±âÀú¼¼Æ÷¾Ï(Ðñî¼á¬øàäß)
  • adenoid squamous cell carcinoma
    ¼±»ó ÆíÆò »óÇǼ¼Æ÷(àÍßÒ ø·øÁ ß¾ù«á¬øà) ¾Ï
  • adult T Cell leukemia virus
    ¼ºÀÎ T ¼¼Æ÷ ¹éÇ÷º´ ¹ÙÀÌ·¯½º
  • adult T cell leukemia virus (HTLV)
    ¼ºÀÎT¼¼Æ÷ ¹éÇ÷º´ ¹ÙÀÌ·¯½º
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
  • habitat factor
    ȯ°æÀÎÀÚ(Ì·Ë­ËöËö), ÁÖ°Å ÀÎÀÚ.
  • hageman factor
    ÇϰԸ¸ ÀÎÀÚ, Hageman ÀÎÀÚ
  • hematopoietic growth factor
    Á¶Ç÷¼ºÀåÀÎÀÚ
  • hemorrhagic diathesis,clotting factor abnormalities
    ÀÀ°íÀÎÀÚ ÀÌ»ó
  • hepatocyte growth factor
    °£¼¼Æ÷¼ºÀåÀÎÀÚ
  • histamine sensitizing factor =HSF
    È÷½ºÅ¸¹Î°¨ÀÛÀÎÀÚ(¡­ÊïíÂì×í­).
  • homologous restriction factor
    µ¿Á¾Á¦ÇÑÀÎÀÚ
  • host factor
    ¼÷ÁÖÀÎÀÚ
  • host integration factor (HIF)
    ¼÷ÁÖÅëÇÕÀÎÀÚ
  • hunter blood factor
    ÇåÅÍÇ÷¾×ÀÎÀÚ(?Ì´Ëâ ËöËö).
  • hunter blood factor
    ÇåÅÍÇ÷¾×ÀÎÀÚ(¡­úìäû ì×í­).
  • hyperglycemic glycogenolytic factor
    °íÇ÷´ç¼º ´ç¿øºÐÇØ(¼º) ÀÎÀÚ.
  • hypothalamic releasing factor
    ½Ã»óÇϺιæÃâÀÎÀÚ.
  • hypothalamic releasing factor
    ½Ã»óÇϺÎÀ¯¸®ÀÎÀÚ(ë¤×ãì×í­).
  • hypothalamus releasing factor
    ½Ã»óÇϺÎÀ¯¸®ÀÎÀÚ.
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
  • Serous cell
    Àå¾×¼¼Æ÷
    [¿¾ ¿ë¾î] Àå¾×¼¼Æ÷
  • Germ cell
    Á¾ÀÚ¼¼Æ÷
    [¿¾ ¿ë¾î] Á¾¼¼Æ÷
  • Glomus cell
    Å丮¼¼Æ÷
    [¿¾ ¿ë¾î] ±¸»ó¼¼Æ÷
  • Tendon cell
    ÈûÁÙ¼¼Æ÷
    [¿¾ ¿ë¾î] °Ç¼¼Æ÷
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
  • L-L factor
    "L-L ÀÎÀÚ(ì×í­), (å²) Laki-Lorand ÀÎÀÚ(ì×í­)"
  • lymph node permeability factor
    ¸²ÇÁÀý(ï½)Åõ°úÀÎÀÚ(÷âΦì×í­)
  • lymphocyte-derived chemotactic factor
    ¸²ÇÁ±¸-À¯µµ(ë¯Óô) È­ÇÐÁÖ¼ºÀÎÀÚ(ûùùÊñËà÷ì×í­)
  • macrophage activation factor
    ´ë½Ä¼¼Æ÷Ȱ¼ºÀÎÀÚ(ÓÞãÝá¬øàüÀàõì×í­)
  • macrophage inhibition factor
    ´ë½Ä¼¼Æ÷ÀúÇØÀÎÀÚ(ÓÞãÝá¬øàîÁúªì×í­)
  • maize factor
    ¿Á¼ö¼ö ÀÎÀÚ(ì×í­)
  • maturation factor
    ¼º¼÷ÀÎÀÚ(à÷âÙì×í­)
  • migration enhancement factor
    À̵¿Ç×Áø ÀÎÀÚ(ì¹ÔÑùñòäì×í­)
  • migration inhibition factor
    À̵¿ÀúÇØ ÀÎÀÚ(ì¹ÔÑîÁúªì×í­)
  • mitogenic factor
    ºÐ¿­ÃËÁøÀÎÀÚ(ÝÂÖ®õµòäì×í­)
  • multiple factor hypothesis
    ´ÙÀÎÀÚ¼³(Òýì×í­àã)
  • nerve growth factor
    ½Å°æ¼ºÀåÀÎÀÚ(ãêÌèà÷íþì×í­)
  • oligomycin-sensitivity-conferring factor
    ¿Ã¸®°í¸¶À̽а¨¼ö¼ººÎ¿©ÀÎÀÚ(Êïáôàõݾæ¨ì×í­)
  • particle scattering factor
    ÀÔÀÚ »ê¶õÀÎÀÚ(Ø£í­ß¤Õ¯ì×í­)
  • pellagra-preventaive factor
    Æç¶ó±×¶ó ¿¹¹æÀÎÀÚ(çãÛÁì×í­)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 15
CSF cancer family syndrome; cerebrospinal fluid; cold stability factor; colony-stimulating factor; coron...
DRF Daily Rating Form; daily replacement factor; Deafness Research Foundation; dose reduction factor
EDF eosinophil differentiation factor; erythroid differentiation factor; extradural fluid
EIF erythrocyte initiation factor; eukaryotic initiation factor
FF degree of fineness of abrasive particles; fat-free; father factor; fecal frequency; fertility factor...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 15
AEC Alveolar epithelial cell
ALCL Anaplastic large cell lymphoma
TCR Anti-T cell receptor
AECA Anti-endothelial cell antibodies
RBC Anti-red blood cell
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • cell differentiation
    ¼¼Æ÷ ºÐÈ­
    ¼¼Æ÷µéÀÌ Á¶Á÷ÀÇ ´Ù¾çÇÑ ±âº» ¼¼Æ÷ ´ÜÀ§·Î ¼ºÀåÇÏ´Â °Í. »óÇǼ¼Æ÷, ½Å°æ¼¼Æ÷
  • cell division
    ¼¼Æ÷ ºÐ¿­
    ÇϳªÀÇ ¼¼Æ÷°¡ µÑ ÀÌ»óÀ¸·Î ³ª´©¾îÁö´Â ÀÏ. º¸Åë ÇÙ ºÐ¿­ÀÌ ¼¼Æ÷Áú ºÐ¿­º¸´Ù ¸ÕÀú ÀϾ´Ù. ÀÌ ÇÙ ºÐ¿­Àº ´ëºÎºÐÀÇ °æ¿ì À¯»çºÐ¿­À̸ç, À¯»çºÐ¿­Àº ¿°»öüÀÇ ºÐ¹è¿Í °°Àº Áß¿äÇÑ ÀÏÀ» ÇÑ´Ù. ü¼¼Æ÷ ºÐ¿­°ú °¨¼ö ºÐ¿­ ¾çÂÊ¿¡¼­ º¸ÀδÙ. ü¼¼Æ÷ ºÐ¿­ÀÇ ÇÙ ºÐ¿­Àº Àü±â, Áß±â, Èıâ, ¸»±â·Î ³ª´©¾îÁø´Ù. ºÐ¿­ °á°ú ¸¸µé¾îÁø µþ ¼¼Æ÷µéÀº ¸ð¼¼Æ÷¿Í µ¿ÀÏÇϸç, ÇÙ³»ÀÇ À¯Àü¹°ÁúÀº Á¤È®ÇÏ°Ô º¹Á¦µÇ¾î 2°³ÀÇ µþ ¼¼Æ÷·Î ³ª´©¾îÁ® µé¾î°£´Ù. °¨¼ö ºÐ¿­Àº »ý½Ä ¼¼Æ÷¸¦ Çü¼ºÇÒ ¶§ ÀϾ´Â ºÐ¿­·Î¼­, ±× °á°ú ¿°»öüÀÇ ¼ö°¡ ü¼¼Æ÷¿¡ ºñÇÏ¿© ¹ÝÀ¸·Î °¨¼ÒÇÑ´Ù. ±×¸®°í ü¼¼Æ÷ ºÐ¿­ÀÇ ÇÙ ºÐ¿­¿¡ ¾Õ¼­ ÀÌÇü ÇÙ ºÐ¿­ÀÎ Á¦1ºÐ¿­ÀÌ Á¸ÀçÇÑ´Ù. ¼¼Æ÷ ºÐ¿­ °úÁ¤À» »ìÆìº¸¸é, ºÐ¿­¿¡¼­ ´ÙÀ½ ºÐ¿­±îÁöÀÇ ½Ã±â¸¦ °£±â ¶Ç´Â ÈÞÁö±â¶ó°í ÇÑ´Ù. ÀÌ °£±â¿¡´Â ¼¼Æ÷³»ÀÇ ¹°Áú´ë»ç³ª °íºÐÀÚ ÇÕ¼ºÀÌ ÀϾ°í, DNA µîÀÇ ¿°»öü ¹°ÁúÀÇ º¹Á¦µµ ÀϾ´Ù. ºÐ¿­ Á÷ÈÄ Çü¼ºµÈ µþ ¼¼Æ÷´Â °£±â¿¡ Á¡Â÷ Ä¿Á® ÇÙµµ 2¹è·Î ÀÚ¶õ´Ù. °£±â ±â°£Àº µ¿¹°, ½Ä¹°, Á¾, ǰÁ¾, Á¶Á÷, ±â°üÀÇ Â÷ÀÌ, ¿Âµµ, ¿µ¾ç µî¿¡ µû¶ó ´Ù¸£¸ç, ¼ö ½Ã°£ ¶Ç´Â ¼ö½Ê ½Ã°£¿¡ À̸£´Â °æ¿ì°¡ ¸¹´Ù. °£±âÀÇ ÇÙÀº ÇÙ ºÐ¿­À» ¾È ÇÒ »Ó ¹°Áú´ë»ç´Â ¿Õ¼ºÇÏ´Ù. À¯»çºÐ¿­¿¡ ÀÇÇØ ¿°»öü°¡ 2°³ÀÇ ÇÙÀ¸·Î ³ª´©¾îÁø ÈÄ ¼¼Æ÷Áú ºÐ¿­ÀÌ ÀϾ´Ù. ºÐ¿­±â¿¡ µé¾î¼­¸é ¿ì¼± ÇÙÀÌ Àü±â, Áß±â, Èıâ, ¸»±â¸¦ °ÅÃÄ µþ ¼¼Æ÷°¡ Çü¼ºµÈ´Ù. ¨ç Àü±â : ÇÙ ¾ÈÀÇ ¿°»ö»ç°¡ ³ª¼±ÇüÀ¸·Î ²¿¿© µÎ²®°í ª¾ÆÁ® ²ö ¸ð¾çÀÇ ¿°»öü°¡ µÈ´Ù. ¿°»öü´Â 2°³ÀÇ ¿°»ö ºÐü°¡ ºÙ¾î ÀÖ´Â ¸ð¾çÀ¸·Î µÇ¾î ÀÖÀ¸¸ç, µ¿½Ã¿¡ ÇÙ¸·, ÀÎÀÌ ¼Ò½ÇµÈ´Ù. °íµî½Ä¹°À» Á¦¿ÜÇÑ ´ëºÎºÐÀÇ ¼¼Æ÷µéÀº ÇÑ ½ÖÀÇ Á߽ɸ³ÀÌ ÇÙ¸· ¹Ù±ùÂÊ¿¡ À§Ä¡ÇÑ´Ù. Á߽ɸ³Àº ¸ÕÀú ºÐ¿­ÇÑ ÈÄ À̵¿À» ½ÃÀÛÇÏ¿© ¾ç±Ø¿¡ µµ´ÞÇÑ´Ù. Áß½Éü°¡ ¾ø´Â ¼¼Æ÷¿¡¼­´Â ¾ç±ØÀ¸·ÎºÎÅÍ ¹æÃßü°¡ »ý±â±â ½ÃÀÛÇϴµ¥, À̸¦ ±Ø¸ð¶ó ÇÑ´Ù. µ¿½Ã¿¡ ¾ç±Ø ¶Ç´Â Áß½Éü¸¦ Áß½ÉÀ¸·Î ÇÏ¿© º°ºû ¸ð¾ç ¶Ç´Â ½Ç ¸ð¾ç ±¸Á¶¸¦ ÅëÆ²¾î ¼º»óü¶ó°í ÇÑ´Ù. À¯»çºÐ¿­ ±â°£ Áß Àü±â°¡ °¡Àå ±ä ½Ã°£À» Â÷ÁöÇÑ´Ù. ¨è Áß±â : ±¸ÇüÀÎ ÇÙÀÌ Å¸¿øÇüÀÌ µÇ¸ç ºñ¿°»öÁúÀº ¹æÃßÇüÀÇ ¹æÃßü¸¦ ÀÌ·ç¸é¼­ Àûµµ¸é
  • cell enclosure
    ¼¼Æ÷ ºÀÀÔü
    ¹ÙÀÌ·¯½º¿¡ °¨¿°µÈ ¼¼Æ÷³»¿¡ ±èÀÚ ¾× µî¿¡ ÀÇÇØ ¿°»öµÈ °ú¸³»ó ¶Ç´Â ±× ¹ÛÀÇ Æ¯Â¡ÀÌ ÀÖ´Â ÇüŸ¦ º¸ÀÌ´Â ¼Òü. °£´ÜÈ÷ ºÀÀÔü¶ó°íµµ ÇÑ´Ù. ±¤°ßº´ µî ¹ÙÀÌ·¯½º º´À» Áø´ÜÇÏ´Â µ¥ ÀÌ¿ëµÇ´Â ¼¼Æ÷ ºÀÀÔüÀÇ º»·¡ ÇüÅ¿¡ °üÇÑ ³íÀǰ¡ ¸¹¾ÒÀ¸³ª, Áö±ÝÀº ¹ÙÀÌ·¯½º º´ÀÇ º´¿øÃ¼ÀÓÀÌ È®ÀεǾú´Ù. ¼¼Æ÷ ºÀÀÔü¿¡´Â ¼¼Æ÷Áú³» ºÀÀÔü¿Í ¼¼Æ÷ÇÙ³» ºÀÀÔü°¡ ÀÖ´Ù. ¼¼Æ÷Áú³» ºÀÀÔü¿¡´Â õ¿¬µÎ, ¿ìµÎÀÇ °¡¸£´Ï¿¡¸® ¼Òü, ±¤°ßº´ÀÇ ³×±×¸® ¼Òü µîÀÌ ÀÖ´Ù. À̵éÀº È£»ê¼º, ¿øÇü, ±ÕÁú ¶Ç´Â °ú¸³»ó ±¸Á¶¸¦ °¡Áø °Í°ú Æ®¶óÄÚ¸¶ÀÇ ÇÁ·Î¹Ùüũ ¼Òü µî È£¿°±â¼ºÀ¸·Î º¹ÀâÇÑ ÇüÀ» °¡Áø °ÍÀÌ ÀÖ´Ù. ¼¼Æ÷ÇÙ³» ºÀÀÔü¿¡´Â Ç츣Æä½º À¯¹ß ¹ÙÀÌ·¯½º·Î Çü¼ºµÈ ºÀÀÔü°¡ ÀÖ´Ù. ¼¼Æ÷ ºÀÀÔü¸¦ ÇÔÀ¯ ³»¿ë¹°¿¡ µû¶ó ºÐ·ùÇϸé, ¹ÙÀÌ·¯½º°¡ ¸ðÀÎ °Í°ú ¹ÙÀÌ·¯½º ±¸¼º ¹°Áú·Î µÈ °ÍÀÌ ¸ðÀÎ °Í, ±×¸®°í ¹ÙÀÌ·¯½ºÀÇ ¼ººÐ°ú °ü·ÃÀÌ ¾ø´Â ƯÀ¯ÇÑ ´Ü¹éÁú·Î ÀÌ·ç¾îÁø °Í µî 3Á¾·ù·Î ³ª´¶´Ù. ¼¼Æ÷ ºÀÀÔüÀÇ Çü¼ºÀº ÁÖ·Î ¹ÙÀÌ·¯½ºÀÇ °¨¿°°ú °ü·ÃµÇ³ª À̿ܿ¡µµ Áß±Ý¼Ó µîÀÇ ¾àǰ Åõ¿©³ª ¼¼Æ÷´ë»ç Àå¾Ö¸¦ ÀÏÀ¸Å°´Â °Í¿¡ ÀÇÇÏ¿© ³ªÅ¸³ª±âµµ ÇÑ´Ù. ¿¹¸¦ µé¸é, ÁßÃ߽Űæ°èÀÇ ÁúȯÀÎ ÆÄŲ½¼ º´ÀÇ °æ¿ì ½Å°æ¼¼Æ÷³»¿¡¼­ ·¹ºß ¼Òü¶ó´Â ¼Òü¸¦, ¹Ì¿ÀŬ·Î´©½º °£Áú ȯÀÚÀÇ ³ú³ª ô¼öÀÇ ½Å°æ¼¼Æ÷³»¿¡¼­´Â ¹Ì¿ÀŬ·Î´©½º ¼Òü¸¦ º¼ ¼ö Àִµ¥ À̵éÀº ¸ðµÎ ¼¼Æ÷Áú³» ºÀÀÔüÀÌ´Ù.
  • cell fusion
    ¼¼Æ÷ ÀÀÇÕ, ¼¼Æ÷ À¶ÇÕ
    µÎ Á¾·ù ÀÌ»óÀÇ ¼¼Æ÷¸¦ ¹ÙÀÌ·¯½º,
  • cell harverter
    ¼¼Æ÷ ȸ¼ö±â
    ´Ù¼öÀÇ ¼¼Æ÷ ¹è¾ç ¿ë±â¿¡¼­ µ¿½Ã¿¡ ¹è¾çµÈ ´É·üÀÌ ÁÁÀº ¼¼Æ÷¸¦ äÃëÇÏ´Â ±â±âÀÇ ÃÑĪ.
  • cell hybridization
    ¼¼Æ÷ ÇÏÀ̺긮µå Çü¼º
  • cell injury
    ¼¼Æ÷ ¼Õ»ó
  • cell interface
    ¼¼Æ÷ »çÀÌ ¸é, ¼¼Æ÷ °£¸é
  • cell kinetics
    ¼¼Æ÷ ¿ªÇÐ
  • cell lethality
    ¼¼Æ÷ Ä¡»çÀ²
  • cell line
    ¼¼Æ÷°è
  • cell mass
    ¿ø±â ¼¼Æ÷±º
  • cell mediated immunity
    ¼¼Æ÷ ¸Å°³ ¸é¿ª, ¼¼Æ÷ ¸Å°³¼º ¸é¿ª ÀÛ¿ë, ¼¼Æ÷¼º ¸é¿ª
    Ç׿øÀÌ T Àӯı¸¸¦ ÀÚ±ØÇÏ¸é ¸é¿ª ±Û·ÎºÒ¸°À» ÇÕ¼º ºÐºñÇÏ´Â °ÍÀÌ ¾Æ´Ï°í Àӯı¸ ÀÚ½ÅÀÌ Ç×ü·Î ÀÛ¿ëÇÏ´Â °¨ÀÛ Àӯı¸°¡ µÇ´Â °ÍÀÌ Ã¼¾×¼º ¸é¿ª°úÀÇ Â÷ÀÌ·Î, ü¾×¼º ¸é¿ªÀÌ ÁÖ·Î ±Þ¼º ¼¼±Õ¼º Áúȯ¿¡ ´ëÇÑ ¸é¿ª ±âÀüÀε¥ ºñÇØ¼­ ¼¼Æ÷¼º ¸é¿ªÀº ¸¸¼º ¼¼±Õ¼º Áúȯ, Á¶Á÷ À̽Ä, ¾Ï ¼¼Æ÷, °õÆÎÀÌ Áúȯ, ƯÈ÷ ¹ÙÀÌ·¯½º Áúȯ¿¡ ´ëÇÑ ¸é¿ª ±âÀüÀÌ´Ù.
  • cell mediated lympholysis
    ¼¼Æ÷ ¸Å°³ ¸²ÇÁ±¸ ¿ëÇØ
  • cell mediated reaction
    ¼¼Æ÷ ¸Å°³¼º ¹ÝÀÀ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 15
insulin like growth factor <growth factor> Insulin like growth factors I and II are polypeptides with considerable sequence similarity to insulin.
They are capable of eliciting the same biological responses, including mitogenesis in cell culture. On the cell surface, there are two types of insulin like growth factor receptor, one of which closely resembles the insulin receptor (which is also present).
Insulin like growth factor I = somatomedin A = somatomedin C
Insulin like growth factor II = MSA (Multiplication stimulating activity).
Insulin like growth factor 1 is released from the liver in response to growth hormone.
Acronym: IGF
(18 Nov 1997)
insulin-like growth-factor binding protein 1 One of the six homologous proteins that specifically bind insulin-like growth factors (somatomedins) and modulate their mitogenic and metabolic actions. The function of this protein is not completely defined. However, several studies demonstrate that it inhibits igf binding to cell surface receptors and thereby inhibits igf-mediated mitogenic and cell metabolic actions. (proc soc exp biol med 1993;204(1):4-29)
(12 Dec 1998)
insulin-like growth factor-binding protein 2 One of the six homologous soluble proteins that bind insulin-like growth factors (somatomedins) and modulate their mitogenic and metabolic actions at the cellular level.
(12 Dec 1998)
insulin-like growth factor binding protein 3 One of the six homologous soluble proteins that bind insulin-like growth factors (somatomedins) and modulate their mitogenic and metabolic actions at the cellular level.
(12 Dec 1998)
insulin like growth-factor-binding protein 4 One of the six homologous soluble proteins that bind insulin-like growth factors (somatomedins) and modulate their mitogenic and metabolic actions at the cellular level.
(12 Dec 1998)
insulin-like growth-factor-binding-protein 5 One of the six homologous soluble proteins that bind insulin-like growth factors (somatomedins) and modulate their mitogenic and metabolic actions at the cellular level.
(12 Dec 1998)
insulin-like-growth-factor-binding protein 6 One of the six homologous soluble proteins that bind insulin-like growth factors (somatomedins) and modulate their mitogenic and metabolic actions at the cellular level.
(12 Dec 1998)
insulin-like growth-factor-binding proteins A family of soluble proteins that bind insulin-like growth factors and modulate their biological actions at the cellular level. (int j gynaecol obstet 1992;39(1):3-9)
(12 Dec 1998)
insulin-like growth factor I <chemical> A well-characterised basic peptide believed to be secreted by the liver and to circulate in the blood. It has growth-regulating, insulin-like, and mitogenic activities. This growth factor has a major, but not absolute, dependence on somatotropin. It is believed to be mainly active in adults in contrast to insulin-like growth factor II, which is a major foetal growth factor.
Chemical name: Insulin-like growth factor I
(12 Dec 1998)
insulin-like growth factor II <chemical> A well-characterised neutral peptide believed to be secreted by the liver and to circulate in the blood. It has growth-regulating, insulin-like and mitogenic activities. The growth factor has a major, but not absolute, dependence on somatotropin. It is believed to be a major foetal growth factor in contrast to insulin-like growth factor I, which is a major growth factor in adults.
Chemical name: Insulin-like growth factor II
(12 Dec 1998)
integrin modulating factor 1 <chemical> A lipid that alters the function of leukocyte integrins; may be an unsaturated fatty acid or an isoprenoid acid
Synonym: imf 1, imf-1
(05 Dec 1998)
intrinsic factor A mucoprotein normally secreted by the epithelium of the stomach and that binds vitamin B12, the intrinsic factor/B12 complex is selectively absorbed by the distal ileum, though only the vitamin is taken into the cell.
(18 Nov 1997)
osteoclast activating factor A lymphokine that stimulates bone resorption and inhibits bone-collagen synthesis.
(05 Mar 2000)
termination factor <molecular biology> Any of several proteins in the cytosol that cut a completed polypeptide loose from a ribosome.
(13 Jan 1998)
testis-determining factor The product of a gene on the short arm of the Y chromosome that is responsible for production of testes.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 15
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 15
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 15
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 15
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 15
ÅëÇÕ°Ë»ö ¿Ï·á